摘要
目的 分析愈癫汤联合利培酮治疗精神分裂症(SZ)的临床疗效.方法 前瞻性选取2021年9月至2023年8月于黑龙江神志医院治疗的SZ患者80例,依据随机数字表法分为试验组(n=40)、对照组(n=40).对照组给予利培酮治疗,试验组给予愈癫汤联合利培酮治疗,两组均治疗8周.观察两组治疗前、治疗8周后的精神症状、睡眠脑电活动指标[N1期、N3期、睡眠效率(SE)及总睡眠时间(TST)]、血清神经生化指标[脑源性神经营养因子(BDNF)、神经生长相关蛋-43(GAP-43)、瞬时受体电位通道1(TRPC1)]水平以及不良反应.结果 治疗8周后,试验组一般精神病理、阳性症状、阴性症状评分及总分分别为(24.75±2.67)、(14.72±1.62)、(14.65±1.60)、(54.12±5.70)分,均低于对照组[(29.73±3.20)、(18.94±2.11)、(18.27±2.06)、(66.94±6.87)分],差异均有统计学意义(P＜0.05).试验组 N1 期为(39.64±4.14)min,小于对照组[(48.96±5.21)min],N3 期眠、SE 及 TST 分别为(85.09±8.78)min、(91.28±9.33)％、(340.28±36.88)min,均大于对照组[(76.46±7.93)min、(80.85±8.43)％、(287.96±30.19)min],差异均有统计学意义(P＜0.05).试验组血清BDNF、GAP-43、TRPC1水平分别为(45.07±4.81)ng/mL、(1.80 ±0.20)μg/L、(696.28±72.05)pg/mL,均高于对照组[(38.06±4.08)ng/mL、(1.64±0.18)μg/L、(627.96±64.93)μg/mL],差异均有统计学意义(P＜0.05).试验组总有效率为92.50％,大于对照组(72.50％),差异有统计学意义(P＜0.05).试验组不良反应发生率为10.00％,低于对照组(30.00％),差异有统计学意义(P＜0.05).结论 愈癫汤联合利培酮治疗SZ可有效改善患者精神症状、睡眠脑电活动及神经生化指标,疗效显著,安全性高.
Abstract
Objective To analyze the clinical efficacy of Yudian decoction combined with risperidone in the treatment of schizophrenia(SZ).Methods Eighty SZ patients treated in Heilongjiang Mental Hospital from September 2021 to August 2023 were prospectively selected and divided into experimental group(n=40)and control group(n=40)according to random number table method.The control group was treated with risperidone,and the experimental group was treated with Yudian decoction combined with risperidone,two groups were treated for 8 weeks.The mental symptoms,sleep brain electrical activity indicators[N1,N3,sleep efficiency(SE),total sleep time(TST)],serum neurobiochemi-cal indices[brain-derived neurotrophic factor(BDNF),growth associated protein-43(GAP-43),transient receptor potential channel 1(TR-PC1)]of the two groups before and after 8 weeks of treatment and adverse reaction were observed and compared.Results After 8 weeks of treat-ment,the scores of general psychopathology,positive symptom,negative symptom and total score of experimental group were(24.75±2.67),(14.72±1.62),(14.65±1.60),(54.12±5.70)scores,respectively,which were lower than those of control group[(29.73±3.20),(18.94±2.11),(18.27±2.06),(66.94±6.87)scores],the differences were statistically significant(P＜0.05).The N1 phase of experi-mental group was(39.64±4.14)min,which was smaller than that of control group[(48.96±5.21)min],N3 sleep,SE and TST of experi-mental group were(85.09±8.78)min,(91.28±9.33)％,(340.28±36.88)min,respectively,which were higher than those of the control group[(76.46±7.93)min,(80.85±8.43)％,(287.96±30.19)min],the differences were statistically significant(P＜0.05).The lev-els of serum BDNF,GAP-43 and TRPC1 in experimental group were(45.07±4.81)ng/mL,(1.80±0.20)μg/L,(696.28±72.05)μg/mL,respectively,which were higher than those in control group[(38.06±4.08)ng/mL,(1.64±0.18)μg/L,(627.96±64.93)μg/mL],the differences were statistically significant(P＜0.05).The total effective rate of the experimental group was 92.50％,which was higher than that of the control group(72.50％),the difference was statistically significant(P＜0.05).The incidence of adverse reactions in the experimen-tal group was 10.00％,which was lower than that in the control group(30.00％),and the difference was statistically significant(P＜0.05).Conclusion Yudian Decoction combined with risperidone in the treatment of SZ can effectively improve the mental symptoms,sleep brain electri-cal activity and neurobiochemical indexes of patients,with significant efficacy,high security.
基金项目
国家自然科学基金(81973747)
黑龙江省中医药科研项目(ZHY2020-183)
黑龙江省中医药局中医药科研课题(2022)(ZHY2022-050)
维普
万方数据